company background image
MEIP

MEI Pharma NasdaqCM:MEIP Stock Report

Last Price

US$0.23

Market Cap

US$31.3m

7D

-43.4%

1Y

-90.9%

Updated

10 Dec, 2022

Data

Company Financials +
MEIP fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MEIP Stock Overview

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.

MEI Pharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MEI Pharma
Historical stock prices
Current Share PriceUS$0.23
52 Week HighUS$2.80
52 Week LowUS$0.22
Beta0.84
1 Month Change-23.75%
3 Month Change-57.13%
1 Year Change-90.89%
3 Year Change-88.37%
5 Year Change-89.07%
Change since IPO-99.95%

Recent News & Updates

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Nov 19
Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Recent updates

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Nov 19
Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

May 18
We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Mar 26
Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Feb 12
Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Dec 02
Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Nov 04
We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Feb 25
The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Feb 11
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

MEI Pharma (NASDAQ:MEIP) Shareholders Have Enjoyed An Impressive 121% Share Price Gain

Jan 15
MEI Pharma (NASDAQ:MEIP) Shareholders Have Enjoyed An Impressive 121% Share Price Gain

What Can We Learn About MEI Pharma's (NASDAQ:MEIP) CEO Compensation?

Dec 11
What Can We Learn About MEI Pharma's (NASDAQ:MEIP) CEO Compensation?

Shareholder Returns

MEIPUS BiotechsUS Market
7D-43.4%-3.0%-3.6%
1Y-90.9%-9.0%-20.6%

Return vs Industry: MEIP underperformed the US Biotechs industry which returned -8.6% over the past year.

Return vs Market: MEIP underperformed the US Market which returned -19.6% over the past year.

Price Volatility

Is MEIP's price volatile compared to industry and market?
MEIP volatility
MEIP Average Weekly Movement15.3%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: MEIP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: MEIP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2000102Dan Goldhttps://www.meipharma.com

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.

MEI Pharma, Inc. Fundamentals Summary

How do MEI Pharma's earnings and revenue compare to its market cap?
MEIP fundamental statistics
Market CapUS$31.32m
Earnings (TTM)-US$53.57m
Revenue (TTM)US$41.67m

0.8x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MEIP income statement (TTM)
RevenueUS$41.67m
Cost of RevenueUS$0
Gross ProfitUS$41.67m
Other ExpensesUS$95.24m
Earnings-US$53.57m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin100.00%
Net Profit Margin-128.55%
Debt/Equity Ratio0%

How did MEIP perform over the long term?

See historical performance and comparison